SOURCE: Novo Nordisk A/S

November 30, 2009 09:19 ET

Novo Nordisk A/S: Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - November 30, 2009) - Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 23 November 2009, the following transactions have been made under the programme:

                 Number of Average             Transaction
                  shares   purchase   value,                   DKK
announcement     5,793,599                              1,855,251,898
23 November 2009    80,000 330.6200                        26,449,600
24 November 2009   100,000 324.2499                        32,424,990
25 November 2009    75,000 323.7000                        24,277,500
26 November 2009    60,000 328.3200                        19,699,200
27 November 2009    75,000 328.1200                        24,609,000
under the
programme        6,183,599                              1,982,712,188

With the transactions stated above, Novo Nordisk owns a total of 30,899,977 treasury shares, corresponding to 4.98% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Company Announcement no 70 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • Further information:


    Mette Kruse Danielsen
    Tel: (+45) 4442 3883
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact


    Mads Veggerby Lausten
    Tel: (+45) 4443 7919
    Email Contact

    Kasper Roseeuw Poulsen
    Tel: (+45) 4442 4471
    Email Contact

    In North America:
    Hans Rommer
    Tel: (+1) 609 919 7937
    Email Contact